首页 | 本学科首页   官方微博 | 高级检索  
     

首发精神分裂症肠道微生物多态性与临床症状及血清代谢组学的关联
引用本文:王雪萍,张于亚楠,卢天兰,卢喆,康哲维,孙瑶瑶,岳伟华. 首发精神分裂症肠道微生物多态性与临床症状及血清代谢组学的关联[J]. 北京大学学报(医学版), 2022, 54(5): 863-873. DOI: 10.19723/j.issn.1671-167X.2022.05.014
作者姓名:王雪萍  张于亚楠  卢天兰  卢喆  康哲维  孙瑶瑶  岳伟华
作者单位:北京大学第六医院,北京大学精神卫生研究所,国家卫生健康委员会精神卫生学重点实验室(北京大学),国家精神心理疾病临床医学研究中心(北京大学第六医院),北京 100191
基金项目:国家重点研发计划项目(2021YFF1201100);国家重点研发计划项目(2016YFC1307000);北京大学医学科技创新平台发展基金(BMU2017PY030);中国医学科学院情感认知障碍综合诊疗关键技术创新单元(2019-I2M-5-006)
摘    要:目的:探索肠道微生物在首发未用药精神分裂症患者与健康对照者间的差异,多维度纵向分析探索抗精神病药物(antipsychotic drugs, APDs)治疗后肠道微生物与临床表型及血清代谢组学的关联。方法:选择2017年6—12月于北京大学第六医院门诊就诊的28例首发未用药的精神分裂症患者(病例组)及同期性别、年龄、受教育程度相匹配的29例健康志愿者(对照组)为研究对象,其中病例组接受了APDs治疗。研究采集病例组入组基线和治疗6周后的粪便和血清样本,并对粪便样本微生物种类和临床症状及血清代谢物进行了检测和分析。结果:菌群多样性分析发现,病例组alpha多样性指数(chao1、ACE、goods_coverage)低于对照组,并且组间差异有统计学意义,病例组与对照组在beta多样性方面有明显的区分。菌群组成分析结果显示Bacteroides、Streptococcus、Romboutsia、Eubacterium ruminantium group在病例组患者接受治疗前后发生变化,且差异具有统计学意义,这些菌群可能反映了APDs治疗的影响。病例组与对照组相比,有更多的微生物种属发生变化...

关 键 词:肠道菌群  精神分裂症  首发未用药  血清代谢组学
收稿时间:2022-06-22

Variations in fecal microbiota of first episode schizophrenia associated with clinical assessment and serum metabolomics
Xue-ping WANG,Yu-ya-nan ZHANG,Tian-lan LU,Zhe LU,Zhe-wei KANG,Yao-yao SUN,Wei-hua YUE. Variations in fecal microbiota of first episode schizophrenia associated with clinical assessment and serum metabolomics[J]. Journal of Peking University. Health sciences, 2022, 54(5): 863-873. DOI: 10.19723/j.issn.1671-167X.2022.05.014
Authors:Xue-ping WANG  Yu-ya-nan ZHANG  Tian-lan LU  Zhe LU  Zhe-wei KANG  Yao-yao SUN  Wei-hua YUE
Affiliation:Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing 100191, China
Abstract:Objective: To explore the role of the microbiota in drug naïve first-onset schizophrenia patients and to seek evidence from multidimensional longitudinal analyses of the intestinal microbiome and clinical phenotype with antipsychotic drugs (APDs) therapy. Methods: In this study, 28 drug naïve first onset schizophrenia patients and age-, gender- and education-matched 29 healthy controls were included, and the patients were treated with APDs. We collected fecal and serum samples at baseline and after 6 weeks of treatment to identify the different microbiota strains and analyse their correlation with clinical symptoms and serum metabolites. The 16S rRNA genes of the gut microbiota were sequenced, and the diversity and relative abundance at the phylum and genus levels were analyzsed in detail. The PANSS score, BMI changed value, and serum metabolome were included in the data analyses. Results: A multiomics study found a potential connection among the clinical phenotype, microbiota and metabolome. The species diversity analyses revealed that the alpha diversity index (chao1, ACE, and goods_coverage) in the schizophrenia APDs group was significantly lower than that in the control group, and the schizophrenia group had clear demarcation from the control group. The microbiota composition analysis results showed that the relative abundance of the genera of Bacteroides, Streptococcus, Romboutsia, and Eubacterium ruminantium group significantly changed after APDs treatment in the schizophrenia patients. These strains could reflect the APDs treatment effect. More genera had differences between the patient and control groups. The LEfSe analysis showed that Prevotella_9 and Bacteroides were enriched in schizophrenia, while Blautia, Dialister, and Roseburia were enriched in the control group. The correlation analysis between microbiota and clinical symptoms showed that Bifidobacterium in schizophrenia was positively correlated with the PANSS reduction rate of the general psychopathology scale. The BMI changed value was positively correlated with the alteration of Clostridium_sensu_stricto_1 during treatment and the baseline abundance of Bacteroides. Moreover, metabolomic data analysis revealed a significant correlation between specific genera and metabolites, such as L-methionine, L-proline, homovanillic acid, N-acetylserotonin, and vitamin B6. Conclusion: Our study found some microbiota features in schizophrenia patients and healthy controls, and several strains were correlated with APDs effects. Furthermore, the multiomics analysis implies the intermediate role of microbiota between antipsychotic effects and serum metabolites and provides new evidence to interpret the difference from multiple levels in the pathogenesis and pharmacological mechanism of schizophrenia.
Keywords:Gut microbiota  Schizophrenia  Drug naïve  Serum metabolomics  
点击此处可从《北京大学学报(医学版)》浏览原始摘要信息
点击此处可从《北京大学学报(医学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号